sirnaaptam
chimera
emerg
one
promis
approach
target
deliveri
sirna
due
modular
diblock
rna
structur
rel
lower
cost
target
deliveri
approach
importantli
outstand
potenti
clinic
translat
howev
addit
challeng
must
address
effici
rna
interfer
rnai
particular
endosom
escap
current
vast
major
sirna
deliveri
vehicl
base
cation
materi
form
complex
neg
charg
sirna
unfortun
approach
complic
formul
form
larg
complex
heterogen
size
unfavor
surfac
charg
colloid
instabl
poor
target
ligand
orient
report
develop
small
simpl
protein
tag
complement
therapeut
target
function
chimera
two
function
domain
dsrna
bind
domain
dsrbd
sirna
dock
phdepend
polyhistidin
disrupt
endosom
membran
protein
select
tag
along
sirna
block
individu
chimera
render
overal
size
complex
small
desir
deep
tissu
penetr
aptam
block
access
target
recognit
interestingli
found
extend
ctermin
polyhistidin
segment
protein
tag
amino
acid
complet
abolish
rna
bind
function
dsrbd
irna
consider
current
interest
elicit
potent
targetspecif
knockdown
virtual
mrna
creat
new
opportun
person
medicin
address
broad
rang
tradit
undrugg
diseas
target
use
small
molecul
similar
antisens
approach
howev
cellspecif
deliveri
sirna
technolog
vivo
still
repres
major
technic
hurdl
guid
sirna
diseas
cell
target
ligand
small
molecul
lipid
peptid
protein
identifi
link
directli
sirna
surfac
sirna
nanocarri
consid
complex
physic
chemic
structur
variou
formul
sirnatarget
liganddeliveri
vehicl
complex
face
difficulti
largescal
product
regulatori
approv
clinic
use
recent
sirnaaptam
chimera
employ
rna
molecul
emerg
highli
promis
approach
cell
typespecif
rnai
owe
low
immunogen
eas
chemic
synthesi
modif
small
size
target
specif
aptam
rnabas
aptam
identifi
vitro
enrich
known
selex
systemat
evolut
ligand
exponenti
enrich
similar
antibodi
capabl
bind
variou
molecular
target
includ
small
molecul
protein
cell
offer
key
advantag
complet
identifi
produc
desir
chemic
modif
vitro
autom
process
aptamerguid
sirna
deliveri
excit
work
mcnamara
dassi
cowork
show
chimera
compos
aptam
target
prostat
specif
membran
antigen
psma
sirna
target
antiapoptot
gene
made
optim
aptam
block
recogn
psma
prostat
tumor
cell
surfac
lead
chimera
cell
intern
wherea
sirna
block
enzymat
cleav
chimera
promot
cell
death
significantli
reduc
tumor
mass
observ
mous
xenograft
model
prostat
tumor
administr
chimera
though
exact
mechan
chimera
endosom
escap
remain
unclear
limit
help
explain
high
concentr
chimera
requir
pioneer
studi
treat
prostat
tumor
obviou
solut
problem
combin
chimera
nanocarri
endosom
ruptur
capabl
common
deliveri
vehicl
includ
lipid
polym
inorgan
nanoparticl
gold
silica
magnet
semiconductor
nanoparticl
sirna
immobil
condens
stabil
enzymat
degrad
endosom
escap
virtual
nanocarri
posit
charg
sirna
complex
unfortun
electrostat
induc
nanocarrierchimera
condens
almost
complet
defi
purpos
simpl
formul
sirna
clinic
translat
final
nanoparticl
becom
complex
mix
size
surfac
properti
aptam
conform
orient
batchtobatch
variat
exampl
size
differ
origin
intact
chimera
nanomet
open
subject
area
drug
deliveri
nanoparticl
final
larg
complex
typic
nanomet
chemic
composit
nanocarri
drastic
chang
chimera
target
profil
vivo
biodistribut
clearanc
furthermor
ideal
make
aptam
loop
structur
expos
sirna
block
hidden
specif
bind
electrostat
condens
cation
nanocarri
warrant
select
demonstr
previous
immobil
sirnaaptam
chimera
onto
cation
nanoparticl
via
sirna
end
offer
significantli
improv
silenc
effect
compar
condens
chimera
onto
cation
nanoparticl
random
site
understand
sinc
exposur
sirna
end
would
increas
chanc
nonspecif
bind
reduc
stabil
sirna
enzymat
degrad
interact
cation
nanocarri
anion
aptam
could
alter
aptam
conform
target
capabl
therefor
critic
import
design
deliveri
system
simpl
potenti
regulatori
approv
mass
product
univers
sirnaaptam
chimera
neutral
sirnabind
specif
ensur
aptam
target
small
avoid
major
alter
chimera
biodistribut
profil
system
simultan
achiev
featur
could
expedit
clinic
translat
highli
promis
sirnaaptam
chimera
technolog
report
develop
small
protein
tag
effici
deliveri
sirnaaptam
chimera
shown
figur
protein
tag
compos
two
function
domain
dsrbd
use
sirna
dock
modul
phdepend
polyhistidin
help
disrupt
endosom
membran
dsrbd
ntermin
region
kda
human
protein
kinas
bind
dsrna
sequenceindepend
fashion
aptam
typic
ssrna
complex
secondari
structur
dsrbd
bind
dsrbd
toler
small
bulg
thu
select
bind
chimera
sirna
end
leav
aptam
end
access
add
endosom
escap
function
short
histidin
oligom
ad
cterminu
dsrbd
incorpor
number
gene
carrier
endosom
buffer
capac
promot
drug
cytoplasm
releas
molecul
pka
valu
approxim
neutral
ph
circul
mainli
deproton
uncharg
desir
posit
charg
counterpart
due
reduc
accumul
within
re
reticuloendotheli
system
acid
compart
endosom
becom
proton
facilit
osmot
swell
lead
cargo
releas
mechan
propos
proton
spong
effect
overal
protein
tag
equal
small
simpl
biodegrad
sirnaaptam
chimera
perfectli
complement
chimera
function
complex
togeth
remain
small
size
discret
stabl
solut
low
posit
charg
circul
simultan
achiev
therapeut
target
endosom
escap
capabl
express
character
dsbrdhi
protein
tag
add
endosom
escap
capabl
short
polyhistidin
peptid
ad
dsrbd
dsrbd
domain
come
first
amino
acid
human
protein
kinas
r
hpkr
two
doublestrand
rna
bind
motif
cooper
dsrnaspecif
bind
toward
n
termin
domin
bind
dsrna
introduc
histidin
peptid
toward
c
termin
figur
minim
impact
dsrbd
biolog
activ
theori
endosom
escap
capabl
increas
longer
chain
hand
long
chain
could
potenti
interfer
dsrbd
protein
fold
bind
achiev
balanc
dsrbd
ctermin
histidin
variou
length
n
n
clone
vector
restrict
enzym
site
introduc
region
pcr
respect
genet
construct
contain
ntermin
clone
vector
ntermin
previous
prove
impact
dsrbd
bind
total
number
encod
final
construct
respect
sequenc
see
method
post
express
purif
result
protein
tag
analyz
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
figur
size
four
protein
tag
show
excel
agreement
theoret
valu
figur
assess
dsrna
bind
activ
sirnaaptam
chimera
label
fluorophor
fam
incub
protein
tag
probe
gel
electrophoresi
agaros
shown
figur
dsrna
bind
capabl
dsrbd
c
terminu
total
well
preserv
compar
dsrbd
without
cterminu
histag
insert
minimum
rna
length
high
affin
bind
dsrbd
determin
basepair
current
rna
length
sirna
segment
adjac
short
stem
aptam
structur
bind
copi
dsrbd
howev
well
document
first
dsrbd
bind
rna
stabli
high
dsrbdrna
ratio
second
copi
dsrbd
bind
significantli
lower
affin
use
unmodifi
dsrbd
sirna
alon
similar
dsrbdsirna
bind
profil
observ
previous
kim
cowork
also
show
enzymat
stabil
sirna
significantli
enhanc
upon
bind
dsrbd
import
mention
key
differ
technolog
compar
prior
work
util
dsrbd
sirna
introduc
highli
posit
charg
peptid
although
posit
charg
nanocarri
promot
sirna
cell
entri
well
known
also
quickli
clear
re
increas
nonspecif
bind
cell
cytotox
furthermor
aforement
avoid
posit
charg
carrier
design
particularli
import
sirnaaptam
chimera
excess
posit
charg
could
nonspecif
interact
aptam
affect
target
capabl
interestingli
gel
electrophoresi
experi
also
reveal
extend
ctermin
anoth
amino
acid
complet
abolish
dsrbd
bind
activ
therefor
follow
gene
express
regul
studi
chose
dsrbd
total
due
balanc
dsrna
bind
endosom
escap
function
comparison
origin
dsrbd
cterminu
control
design
synthesi
character
sirnaaptam
chimera
evalu
univers
protein
tag
sirnaaptam
chimera
first
design
made
chimera
base
protocol
describ
dassi
cowork
take
advantag
shorten
aptam
sequenc
specif
target
psma
well
optim
sirna
strand
enhanc
therapeut
potenc
psma
target
aptam
kept
chimera
psma
identifi
one
attract
cell
surfac
marker
prostat
epitheli
cell
neovascular
endotheli
cell
accumul
retent
psma
target
probe
site
tumor
growth
basi
radioimmunoscintigraph
scan
eg
prostascint
scan
target
therapi
human
prostat
cancer
metastasi
replac
sirna
sequenc
sirna
silenc
gfp
express
gfp
best
model
quantit
assess
silenc
effect
use
optic
imag
flow
cytometri
long
ssrna
compos
psma
aptam
sirna
antisens
strand
figur
prepar
vitro
transcript
presenc
fluoromodifi
pyrimidi
improv
resist
ribonucleas
shown
previous
modif
compat
dsrbd
bind
unlik
substitut
transcript
anneal
chemic
synthes
sirna
sens
strand
combin
chimera
small
protein
tag
first
test
activ
chimera
test
target
function
aptam
block
psmaposit
lncap
psmaneg
prostat
tumor
cell
incub
dyelabel
chimera
shown
figur
chimera
select
bind
enter
lncap
cell
indic
target
specif
test
silenc
effect
separ
chimera
transfect
gfpexpress
prostat
tumor
cell
deriv
lncap
use
convent
transfect
agent
lipofectamin
shown
figur
silenc
effect
indistinguish
posit
control
use
sirna
prove
chimera
enzymat
process
intracellularli
gener
function
sirna
target
deliveri
silenc
cell
biolog
activ
protein
tag
sirnaaptam
chimera
separ
character
proceed
evalu
gene
silenc
effect
simpl
yet
function
highli
complementari
protein
tag
sirnaaptam
chimera
deliveri
gfpexpress
cell
line
use
model
advantag
fluoresc
imag
techniqu
microscopi
quantit
flow
cytometri
figur
f
show
confoc
imag
cell
without
treatment
treat
gfpsirna
alon
chimera
alon
random
sequenc
sirna
protein
tag
chimera
protein
tag
chimera
protein
tag
qualit
experiment
treatment
chimera
protein
tag
clearli
show
gfp
silenc
wherea
none
five
control
treatment
lead
signific
suppress
gfp
express
quantit
flow
cytometri
studi
confirm
result
figur
current
gate
valu
set
gfp
fluoresc
intens
origin
untreat
cell
show
gfpneg
popul
treat
cell
random
sequenc
sirna
protein
tag
show
virtual
chang
popul
differ
total
cell
popul
within
error
rang
prove
sequencespecif
silenc
rnai
cell
treat
gfp
sirna
chimera
gfp
neg
cell
increas
total
cell
popul
respect
even
increas
chimera
concentr
ten
time
mm
total
gfpneg
cell
popul
increas
supplementari
figur
strongli
suggest
need
carrier
materi
direct
comparison
chimera
tag
dsrbdhi
dsrbdhi
show
major
differ
silenc
effici
chang
taken
togeth
result
clearli
indic
chimera
alon
concentr
commonli
use
rnai
experi
lead
effect
silenc
remark
effect
endosom
destabil
sinc
dsrbd
block
ident
structur
function
put
silenc
effici
dsrbdhi
context
convent
rna
deliveri
vehicl
lipofectamin
quantit
flow
cytometri
also
conduct
agreement
microscopi
result
shown
figur
lipofectamin
reduc
gfpneg
cell
origin
chang
supplementari
figur
slightli
effici
protein
tag
howev
import
note
lipofectamin
deliv
chimera
cell
mainli
via
electrostat
interact
posit
charg
lipofectamin
neg
charg
cell
surfac
nontarget
deliveri
wherea
protein
tag
deliv
chimera
cell
typespecif
molecular
recognit
target
deliveri
also
worth
mention
molar
ratio
mix
chimera
protein
tag
sirna
block
bind
copi
dsrbd
although
second
copi
weak
bind
affin
inde
chang
bind
ratio
affect
rnai
effici
supplementari
figur
confirm
differ
endosom
escap
capabl
two
protein
tag
dsrbdhi
dsrbdhi
perform
dual
color
imag
assay
use
nonfluoresc
lncap
cell
experi
chimera
label
endosomelysosom
mark
lysotrack
spectral
distinguish
green
fluoresc
direct
contrast
chimera
distribut
intracellular
densiti
endosomelysosom
observ
two
protein
tag
shown
figur
chimera
evenli
distribut
insid
cell
tag
dsrbdhi
wherea
dsrbdhi
treat
cell
show
much
higher
densiti
endosom
lysosom
lower
level
fluoresc
confoc
imag
comparison
directli
explain
differ
two
protein
tag
rnai
effici
unambigu
demonstr
superior
endosom
escap
capabl
dsrbdhi
dsrbdhi
cytotox
lastli
probe
cytotox
best
perform
protein
tag
dsrbdhi
use
standard
cell
viabil
assay
celltiterblueh
assay
base
abil
live
cell
convert
redox
dye
resazurin
fluoresc
end
product
resorufin
nonviabl
cell
lose
metabol
capac
thu
gener
fluoresc
signal
illustr
figur
virtual
toxic
detect
concentr
four
time
high
one
use
deliveri
work
refer
untreat
control
perhap
surpris
due
biocompat
dsrbd
small
protein
human
origin
importantli
futur
vivo
applic
envis
small
protein
tag
would
improv
clearanc
capabl
compar
synthet
polym
inorgan
nanoparticl
use
sirna
deliveri
discuss
sirnaaptam
chimera
one
promis
approach
cell
typespecif
rnai
owe
low
immunogen
eas
chemic
synthesi
modif
small
size
modular
target
aptam
block
therapeut
sirna
segment
importantli
employ
rna
molecul
simpl
formul
chimerabas
target
sirna
therapi
lead
outstand
clinic
translat
due
incap
chimera
effici
escap
endosom
deliveri
nanocarri
need
howev
almost
current
target
sirna
deliveri
formul
involv
cation
nanocarri
polym
inorgan
nanoparticl
peptid
protein
unfortun
convent
sirna
nanocarri
unsuit
chimera
deliveri
fact
revers
signatur
properti
chimera
simpl
formul
regulatori
approv
clinic
translat
charg
induc
complex
format
basic
aggreg
process
lack
control
aggreg
size
shape
stoichiometri
chimera
orient
aptam
function
reproduc
scaleup
product
addit
final
complex
often
carrier
posit
charg
well
unfavor
system
use
result
first
clinic
trial
sirna
duplex
mainli
limit
local
administr
protein
tag
reli
high
posit
charg
interact
rna
molecul
fact
recogn
rel
long
dsrna
bp
sirna
segment
short
stem
region
aptam
chimera
molecul
extens
biochemistri
investig
shown
current
length
chimera
maximum
two
copi
dsrbd
bind
differenti
affin
first
copi
bind
much
stronger
second
copi
gene
silenc
experi
conduct
reflect
effect
sinc
mix
chimera
protein
tag
affect
silenc
effici
consid
molecular
weight
chimera
kda
protein
tag
kda
molecular
weight
final
complex
bind
becom
kda
base
welldocu
size
effect
vivo
drug
deliveri
size
suffici
larg
reduc
prematur
renal
clearanc
still
small
enough
deep
tissu
penetr
exampl
tag
sirnaaptam
chimera
kda
peg
vivo
circul
halflif
shown
increas
approxim
min
hour
wherea
larg
nanoparticl
nm
shown
ineffect
tumor
treatment
except
hyperperm
tumor
conclus
solv
endosom
escap
problem
highli
promis
sirnaaptam
chimera
base
therapi
design
dualblock
small
protein
combin
dsrbd
polyhistidin
identifi
optim
length
polyhistidin
result
protein
tag
share
simplic
featur
sirnaaptam
chimera
yet
offer
exactli
complementari
function
dsrbd
select
bind
sirna
block
leav
target
aptam
access
term
size
differ
convent
cation
deliveri
vehicl
dsrbdhi
tag
chimera
remain
discret
solut
rather
form
larg
aggreg
term
function
chimera
dsrbdhi
highli
complementari
thu
offer
complet
set
featur
necessari
target
sirna
deliveri
eg
target
therapeut
sirna
protect
endosom
escap
platform
also
univers
abl
chaperon
chimera
sequenc
cell
typespecif
deliveri
larg
base
natur
protein
dsrbdhi
excel
candid
potenti
clinic
translat
simpl
structur
biodegrad
develop
small
protein
tag
vivo
test
rais
excit
opportun
sirna
clinic
translat
person
medicin
materi
vendor
specif
chemic
list
gener
restrict
enzym
obtain
new
england
biolab
cell
cultur
product
purchas
gibcoinvitrogen
chimera
compos
aptam
target
psma
sirna
target
gfp
ssdna
psma
aptam
nucleotid
chemic
synthes
integr
dna
technolog
idt
use
templat
gener
one
strand
sirnaaptam
chimera
amplif
pcr
perform
primer
contain
antisens
strand
gfp
sirna
underlin
primer
contain
rna
polymeras
promot
site
bold
pcr
primer
sequenc
primer
primer
bp
pcr
product
put
ta
clone
pcr
vector
invitrogen
sequenc
posit
plasmid
select
use
templat
pcr
result
pcr
product
separ
agaros
gel
recov
qiaex
ii
gel
extract
kit
qiagen
purifi
pcr
product
use
templat
vitro
transcript
kit
ambion
accord
manufactur
instruct
fluoromodifi
pyrimidin
trilink
san
diego
ad
replac
ctp
utp
rna
molecul
gener
transcript
reaction
anneal
sens
strand
gfp
sirna
chemic
synthes
without
fam
idt
sequenc
fam
anneal
transcript
rna
synthet
sirna
sens
strand
mix
molar
ratio
duplex
buffer
idt
incub
min
follow
slow
cool
hour
final
chimera
store
construct
clone
express
vector
novagen
construct
dsrbdhi
dsrbdhi
obtain
use
fulllength
pkr
gene
clone
id
pcr
templat
dsrbdhi
dsrbdhi
construct
made
graft
addit
histidin
dsrbdhi
plasmid
use
pcr
restrict
enzym
site
introduc
pcr
primer
clone
dsrbdhi
construct
introduc
two
stop
codon
taa
tga
site
three
construct
read
frame
cover
sequenc
vector
ctermin
end
stop
codon
pcr
product
singl
coloni
select
grown
h
circlegrow
medium
contain
mgml
kanamycin
overnight
cultur
dilut
vv
fresh
medium
incub
od
valu
reach
express
induc
addit
isopropylbdthiogalactopyranosid
iptg
mm
cell
growth
continu
anoth
hour
cell
harvest
centrifug
beckman
rotor
g
min
store
cell
suspend
bugbust
mix
novagen
ml
reagent
per
gram
wet
cell
past
bug
buster
mix
ad
proteas
inhibitor
edtafre
cocktail
pierc
glycerol
mm
thp
novagen
cell
suspens
incub
shaker
platform
min
room
temperatur
insolubl
cell
debri
remov
centrifug
beckman
g
min
solubl
extract
load
onto
affin
column
nicharg
bind
resin
novagen
follow
wash
bind
buffer
wash
buffer
desir
protein
elut
volum
elut
buffer
novagen
elut
protein
dialyz
pb
contain
glycerol
vv
bmercaptoethanol
hour
purifi
protein
probe
use
sdspage
stain
coomassi
brilliant
blue
biorad
protein
concentr
determin
biorad
protein
assay
bovin
serum
albumin
standard
function
character
sirnaaptam
chimera
test
function
sirna
block
chimera
describ
gfp
sirna
control
qiagen
final
concentr
nm
transfect
prostat
cancer
cell
stabli
express
gfp
use
lipofectamin
rnai
max
invitrogen
follow
instruct
provid
manufactur
evalu
target
specif
aptam
block
psmaposit
lncap
cell
psmaneg
cell
treat
complex
chimera
dsrbdhi
chimeraprotein
tag
molar
ratio
nm
chimera
serum
free
medium
hour
follow
incub
complet
medium
anoth
h
dapi
nm
ad
stain
cell
nuclei
fluoresc
imag
captur
olympu
invert
microscop
equip
longpass
filter
color
ccd
camera
character
rna
bind
capabl
four
protein
tag
bind
capabl
four
polyhistidin
modifi
dsrbd
protein
evalu
nativ
agaros
gel
chimera
label
fam
end
sirna
sens
strand
idt
prepar
chimeradsrbd
complex
chimera
mm
ml
incub
protein
tag
proteinchimera
molar
ratio
h
bound
chimera
unbound
chimera
quantifi
agaros
gel
use
macro
imag
system
lightool
research
ca
evalu
endosom
escap
psmaexpress
lncap
cell
seed
mm
glassbottom
petri
dish
matteck
corp
densiti
cellswel
hour
rpmi
supplement
fc
complex
chimera
label
idt
protein
tag
ad
lncap
cell
serumfre
medium
hour
follow
incub
complet
medium
hour
lysotrackerh
green
nm
invitrogen
ad
hour
imag
captur
confoc
laser
scan
microscop
lsm
carl
zeiss
germani
microscopi
flow
cytometri
studi
gene
knockdown
efficaci
prostat
cancer
cell
express
gfp
seed
mm
glassbottom
petri
dish
confoc
imag
plate
flow
cytometri
cell
treat
chimera
dsrbdhi
compar
five
control
group
includ
treatment
treat
gfpsirna
alon
chimera
alon
random
sequenc
sirna
protein
tag
chimera
protein
tag
h
serum
free
media
incub
complet
media
h
confoc
imag
obtain
lsm
confoc
microscop
equip
argon
nm
hene
nm
laser
quantit
flow
cytometri
investig
done
bd
facscantoii
flow
cytomet
cytotox
assay
lncap
cell
seed
plate
well
hour
treat
differ
concentr
dsrbdhi
protein
tag
hour
celltiterblu
reagent
ml
ad
well
h
incub
cell
viabil
assess
fluoresc
intens
nm
excit
nm
tecan
infinit
micropl
reader
